Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme receives EU approval for new Ivemend regimen

Merck Sharpe and Dohme receives EU approval for new Ivemend regimen

14th September 2010

Merck Sharpe and Dohme has been granted European regulatory approval for a new regimen of Ivemend (fosaprepitant), its treatment for preventing chemotherapy-induced nausea and vomiting.

The new product is a single-dose 150mg specification which is administered on the first day of treatment for patients undergoing highly emetogenic cisplatin-based and moderately emetogenic chemotherapy.

It is designed to be more convenient than the previous 115mg fosaprepitant regime, which needed to be supplemented with Emend capsules taken on days two and three.

Dr Steven Grunberg, professor of medicine and pharmacology at the University of Vermont, said this will provide a new treatment option against health conditions which are seen as a major concern by many cancer patients.

He added: "The introduction of Ivemend 150 mg will allow healthcare professionals the flexibility to choose a regimen based on the individual needs of our patients."

Earlier this month, the company was granted European regulatory approval for Sycrest, its new treatment for preventing manic episodes among bipolar I disorder sufferers.ADNFCR-8000103-ID-800063558-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.